Mannedorf

Researchers are investigating how bariatric surgery, including Sleeve Gastrectomy SG and Roux-en-Y gastric bypass RYGB, affects eating and drinking behaviors in people with obesity. The study focuses on understanding these behaviors beyond self-reported food intake by using a special device called the drinkometer. This research also explores differences between males and females and examines how changes in gut hormone levels relate to these behaviors and body weight loss over time. The study observes adults with obesity undergoing SG or RYGB surgery, as well as control groups including people with obesity not having surgery and individuals with normal weight. Using the drinkometer, the study measures detailed aspects of ingestive behavior before and up to one year after surgery. Additionally, it investigates hormone levels after eating and compares results between sexes. A subgroup of patients who had RYGB surgery five years ago is also studied to explore long-term associations between ingestive behavior, hormone levels, and weight loss. Participants will undergo assessments of their drinking behavior using the drinkometer device, and blood samples will be taken to measure gut hormone levels. Data collection occurs before surgery and at various times up to one year after, with a separate evaluation for those five years post-surgery. The study measures detailed behavioral patterns, hormone effects, and body weight changes to understand the impact of bariatric surgery. The total study duration varies depending on the participant group, and safety and adherence are monitored throughout the research period.

Gastroentero-pancreatic neuroendocrine tumours GEP-NETs are rare cancers arising from the neuroendocrine cells in the gastrointestinal tract and pancreas. These tumours share common clinical features but their cell biology and mechanisms are not well understood, limiting targeted treatments. The SwissNET registry is designed to collect detailed information to better understand GEP-NETs and improve management strategies in Switzerland. This study collects data prospectively from patients diagnosed with neuroendocrine tumours confirmed by tissue analysis, regardless of the tumours original location. Data entry is anonymized and gathered from hospitals and general practitioners across Switzerland. A study nurse visits contributing centers to review patient files, and a review board addresses conflicting information. The registry monitors treatment approaches including surgery, medical therapy, and peptide-receptor radionuclide therapy. Participants provide informed consent for their data to be included. Researchers regularly evaluate patient outcomes such as tumour-related mortality and hospitalisation rates every five years. The registry also tracks the incidence of GEP-NETs in Switzerland and the effects of different treatments over time. This ongoing data collection aims to improve understanding and guide future care for patients with neuroendocrine tumours.

This research aims to understand how thyroidectomy removal of the thyroid gland complications may differ depending on the thyroid hormone levels before surgery in patients with Graves disease or Amiodarone-induced thyrotoxicosis AIT. It focuses on whether patients with different thyroid metabolic statescontrolled normal hormone levels or uncontrolled elevated hormone levelshave similar rates of complications such as nerve damage, hypoparathyroidism, bleeding, or severe heart events during and after surgery. The study is observational and uses data collected in the EUROCRINE registry from multiple centers in Europe. Patients who undergo thyroidectomy for Graves disease or AIT are grouped based on their hormone levels before surgery, using free triiodothyronine fT3 and free thyroxine fT4 tests taken within one week prior to surgery. The study does not alter the surgery or treatment methods. Data are collected prospectively through the EUROCRINE registry and an additional module for study-specific routine data. The study plans to include about 25 centers over two years and will record details such as surgery duration, blood loss, medications, monitoring techniques, hospital stay, and any complications. Participants will provide informed consent, and their usual surgical care is not changed. Researchers will track outcomes from the day of surgery through an average of two years, including complications and recovery. Data include clinical information, operative details, and postoperative follow-up. The study aims to help refine surgical guidelines and determine if waiting for normal thyroid levels before surgery is necessary, potentially speeding up treatment and reducing risks and costs for patients.